[go: up one dir, main page]

DK3033101T3 - Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab - Google Patents

Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab Download PDF

Info

Publication number
DK3033101T3
DK3033101T3 DK14835826.0T DK14835826T DK3033101T3 DK 3033101 T3 DK3033101 T3 DK 3033101T3 DK 14835826 T DK14835826 T DK 14835826T DK 3033101 T3 DK3033101 T3 DK 3033101T3
Authority
DK
Denmark
Prior art keywords
benralizumab
ser
leu
thr
asthma
Prior art date
Application number
DK14835826.0T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3033101T3 publication Critical patent/DK3033101T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)

Claims (12)

1. Effektiv mængde af benralizumab til anvendelse til behandling af astma, hvor benralizumab administreres til en astmapatient, hvor administrationen reducerer patientens eksacerbationsrate, og hvor benralizumab administreres ved en dosis på 30 mg én gang hver 4. uge i 12 uger og herefter én gang hver 8. uge.
2. Benralizumab til anvendelse ifølge krav 1, hvor astmaen er eosinofil astma.
3. Benralizumab til anvendelse ifølge et hvilket som helst af krav 1 eller 2, hvor patienten har et blodeosinofiltal på mindst 300 celler/μΐ.
4. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor patienten har et forceret ekspiratorisk volumen (FEVi) på mindst 75 % forventet værdi før administration.
5. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor patienten har en score på astmakontrolspørgeskema på mindst 1,5 før administration.
6. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-5, der reducerer den årlige eksacerbationsrate efter administration af antistoffet.
7. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor den årlige eksacerbationsrate reduceres med mindst 35 %, eventuelt med mindst 40 %, eventuelt med mindst 50 %, eventuelt med mindst 60 %.
8. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor patienten anvender højdosis inhalerede kortikosteroider (ICS).
9. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor patienten anvender langtidsvirkende β2-agonister (LABA).
10. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor patienten har eksacerbationer i anamnesen, eventuelt hvor eksacerbationerne i anamnesen omfatter mindst to eksacerbationer i løbet af året forud for administrationen af benralizumab, eventuelt hvor eksacerbationerne i anamnesen ikke omfatter mere end seks eksacerbationer i løbet af året forud for administrationen af benralizumab.
11. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor benralizumab administreres parenteralt, eventuelt hvor benralizumab administreres subkutant.
12. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-11, hvor benralizumab administreres foruden kortikosteroidterapi.
DK14835826.0T 2013-08-12 2014-08-07 Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab DK3033101T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (1)

Publication Number Publication Date
DK3033101T3 true DK3033101T3 (da) 2019-04-08

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14835826.0T DK3033101T3 (da) 2013-08-12 2014-08-07 Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab

Country Status (26)

Country Link
US (2) US9441037B2 (da)
EP (1) EP3033101B1 (da)
JP (4) JP6746495B2 (da)
KR (2) KR102390714B1 (da)
CN (2) CN105451760A (da)
AU (2) AU2014306956B2 (da)
BR (1) BR112016002401A8 (da)
CA (1) CA2918105C (da)
CY (1) CY1122132T1 (da)
DK (1) DK3033101T3 (da)
ES (1) ES2716906T3 (da)
HK (1) HK1221644A1 (da)
HR (1) HRP20190405T1 (da)
HU (1) HUE042607T2 (da)
LT (1) LT3033101T (da)
ME (1) ME03348B (da)
MX (1) MX368508B (da)
PL (1) PL3033101T3 (da)
PT (1) PT3033101T (da)
RS (1) RS58404B1 (da)
RU (1) RU2676333C2 (da)
SG (2) SG11201600481UA (da)
SI (1) SI3033101T1 (da)
SM (1) SMT201900163T1 (da)
TR (1) TR201903312T4 (da)
WO (1) WO2015023504A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3033104T (pt) 2013-08-12 2019-06-27 Astrazeneca Ab Métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumabe
HUE057065T2 (hu) * 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával
CN113230399A (zh) * 2013-10-15 2021-08-10 阿斯利康(瑞典)有限公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
RS62419B1 (sr) * 2013-10-24 2021-10-29 Astrazeneca Ab Stabilne vodene formulacije antitela
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
ES2981555T3 (es) * 2017-01-04 2024-10-09 Worg Pharmaceuticals Zhejiang Co Ltd Péptidos de S-arrestina y usos terapéuticos de los mismos
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283926T1 (de) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1266663A4 (en) 2000-02-15 2003-07-23 Kyowa Hakko Kogyo Kk INDUCER OF EOSINOPHILIC SPECIFIC APOPTOSIS
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Il-5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2685222C (en) * 2007-05-14 2017-12-19 Medimmune, Llc Methods of reducing eosinophil levels
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
CA2781061A1 (en) * 2009-11-18 2011-05-26 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
AU2011343570B2 (en) * 2010-12-16 2016-11-03 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
CA2853858A1 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
HUE057065T2 (hu) * 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával
PT3033104T (pt) 2013-08-12 2019-06-27 Astrazeneca Ab Métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumabe

Also Published As

Publication number Publication date
AU2020201327A1 (en) 2020-03-12
HK1225302B (en) 2017-09-08
ME03348B (me) 2019-10-20
RU2016108723A3 (da) 2018-06-18
BR112016002401A8 (pt) 2018-06-12
JP2024129139A (ja) 2024-09-26
CN111588848A (zh) 2020-08-28
TR201903312T4 (tr) 2019-04-22
SG10202005560UA (en) 2020-07-29
EP3033101A1 (en) 2016-06-22
CY1122132T1 (el) 2020-11-25
ES2716906T3 (es) 2019-06-17
HK1221644A1 (zh) 2017-06-09
PT3033101T (pt) 2019-04-02
MX368508B (es) 2019-10-07
PL3033101T3 (pl) 2019-06-28
KR20220057637A (ko) 2022-05-09
JP2020128375A (ja) 2020-08-27
US9441037B2 (en) 2016-09-13
JP6746495B2 (ja) 2020-08-26
RU2016108723A (ru) 2017-09-19
BR112016002401A2 (pt) 2017-09-12
WO2015023504A1 (en) 2015-02-19
HRP20190405T1 (hr) 2019-04-19
RU2676333C2 (ru) 2018-12-28
US20170198049A1 (en) 2017-07-13
HUE042607T2 (hu) 2019-07-29
CN105451760A (zh) 2016-03-30
RS58404B1 (sr) 2019-04-30
CA2918105A1 (en) 2015-02-19
SI3033101T1 (sl) 2019-04-30
SG11201600481UA (en) 2016-02-26
AU2014306956B2 (en) 2019-11-21
MX2016001383A (es) 2016-08-03
WO2015023504A8 (en) 2015-09-24
SMT201900163T1 (it) 2019-05-10
KR20160042121A (ko) 2016-04-18
KR102390714B1 (ko) 2022-04-26
CA2918105C (en) 2023-02-28
LT3033101T (lt) 2019-03-25
EP3033101A4 (en) 2017-07-12
JP2016527324A (ja) 2016-09-08
JP2022120009A (ja) 2022-08-17
US20150044202A1 (en) 2015-02-12
AU2014306956A1 (en) 2016-02-04
EP3033101B1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
DK3033101T3 (da) Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
CA2917603C (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab